[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-378191-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-378191-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","tiliroside-combined-with-anti-muc1-monoclonal-antibody-as-promising-anti-cancer-strategy-in-ags-cancer-cells","Tiliroside Combined with Anti-MUC1 Monoclonal Antibody as Promising Anti-Cancer Strategy in AGS Cancer Cells","","Specific alterations in mucin-type O-glycosylation are frequent in many cancers, including gastric cancer, affecting glycan synthesis and expression patterns such as truncated Tn/T antigens and fucosylated forms. Tiliroside, a glycosidic dietary flavonoid, has reported anti-cancer activity. This study evaluates whether anti-MUC1 combined with tiliroside modulates cancer-related factors in AGS gastric cancer cells.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/tiliroside-combined-with-anti-muc1-monoclonal-antibody-as-promising-anti-cancer-strategy-in-ags-cancer-cells/378191/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/tiliroside-combined-with-anti-muc1-monoclonal-antibody-as-promising-anti-cancer-strategy-in-ags-cancer-cells/378191.png","ImageObject",300,407,{"name":42,"@type":43},"Rizky","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What cancer-related glycosylation changes are highlighted as common in tumors?","Question",{"text":63,"@type":64},"The text emphasizes mucin-type O-glycosylation changes, including incomplete glycan synthesis, increased truncated O-glycans (Tn/T antigens and sialylated forms), and enhanced fucosylation-related expression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the goal of combining anti-MUC1 with tiliroside in AGS cells?",{"text":68,"@type":64},"The study aims to assess the combined effect on cancer-related factors in AGS gastric cancer cells, focusing on MUC1-related signaling and tumor-associated targets.",{"name":70,"@type":61,"acceptedAnswer":71},"How did the combined therapy compare with monotherapy?",{"text":72,"@type":64},"The combined action of anti-MUC1 and tiliroside was more effective than monotherapy for multiple targets, including C1GalT1, ST3GalT1, FUT4, Gal-3, NF-κB, Akt mRNAs, and Tn antigen, as well as sialyl T antigen expression.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},378191,1790510529,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Article  \nTiliroside Combined with Anti-MUC1 Monoclonal Antibody as Promising Anti-Cancer Strategy in AGS Cancer Cells  \nIwona Radziejewska 1, *, Katarzyna Supruniuk 2, Katarzyna Jakimiuk 3, Michał Tomczyk 3, Anna Bielawska 4 and Anna Galicka 1  \nCitation: Radziejewska, I.;  \nSupruniuk, K.; Jakimiuk, K.; Tomczyk, M.; Bielawska, A.; Galicka, A. Tiliroside Combined with  \nAnti-MUC1 Monoclonal Antibody as Promising Anti-Cancer Strategy in AGS Cancer Cells. Int. J. Mol. Sci. 2023, 24, 13036. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms241713036](10.3390/ijms241713036)  \nAcademic Editors: Antonio Carrillo-Vico and Ivan Cruz-Chamorro  \nReceived: 7 July 2023  \nRevised: 27 July 2023  \nAccepted: 17 August 2023  \nPublished: 22 August 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Medical Chemistry, Medical University of Białystok, ul. Mickiewicza 2a, 15-222 Białystok, Poland; [anna.galicka@umb.edu.pl](anna.galicka@umb.edu.pl)  \n2 Department of Medical Biology and Genetics, Medical University of Gda ´nsk, ul. D˛ebinki 1, 80-211 Gda ´nsk, Poland; [katarzyna.supruniuk@gumed.edu.pl](katarzyna.supruniuk@gumed.edu.pl)  \n3 Department of Pharmacognosy, Faculty of Pharmacy with the Division of Laboratory Medicine, Medical University of Białystok, ul. Mickiewicza 2a, 15-230 Białystok, Poland; [katarzyna.jakimiuk@umb.edu.pl](katarzyna.jakimiuk@umb.edu.pl) (K.J.); [michal.tomczyk@umb.edu.pl](michal.tomczyk@umb.edu.pl) (M.T.)  \n4 Department of Biotechnology, Medical University of Białystok, ul. Kili ´nskiego 1, 15-089 Białystok, Poland; [aniabiel@umb.edu.pl](aniabiel@umb.edu.pl)  \n* Correspondence: [iwona@umb.edu.pl](iwona@umb.edu.pl); Tel.: +48-85-535-934-079  \nAbstract: Specific changes in mucin-type O-glycosylation are common for many cancers, including gastric ones. The most typical alterations include incomplete synthesis of glycan structures, enhanced expression of truncated O-glycans (Tn, T antigens and their sialylated forms), and overexpression offucosylation. Such altered glycans influence many cellular activities promoting cancer development. Tiliroside is a glycosidic dietary flavonoid with pharmacological properties, including anti-cancer. In this study, we aim to assess the effect of the combined action of anti-MUC1 and tiliroside on some cancer-related factors in AGS gastric cancer cells. Cancer cells were treated with 40, 80, and 160 􀀖M tiliroside, 5 􀀖g/mL anti-MUC1, and flavonoid together with mAb. Real-Time PCR, ELISA, and Western blotting were applied to examine MUC1 expression, specific, tumor-associated antigens, enzymes taking part in their formation, Gal-3, Akt, and NF-􀀔B. MUC1 expression was significantly reduced by mAb action. The combined action of anti-MUC1 and tiliroside was more effective in comparison with monotherapy in the case of C1GalT1, ST3GalT1, FUT4, Gal-3, NF-􀀔B, Akt mRNAs, and Tn antigen, as well as sialyl T antigen expression. The results of our study indicate that applied combined therapy may be a promising anti-gastric cancer strategy.  \nKeywords: tiliroside; gastric cancer; glycoforms; MUC1; TACAs  \n1. Introduction  \nGastric cancer (GC) is stated to be the fifth most common cancer and the third most frequent cause of cancer deaths worldwide [1] . Surgery still remains the main treatment for early-diagnosed, operable patients. For advanced GC, new therapeutic methods are currently being studied [2] .  \nIt is reported that many natural plant-based chemical compounds possess anti-cancer properties. They are able to impair and even kill cancer cells without being toxic to healthy cells [3–5] . The main group of such compounds is polyphenols, widely distributed in","cbCait5FH7BAEbD7","https://ap.wps.com/l/cbCait5FH7BAEbD7","pdf",3575598,16,"English","# Abstract\n# Introduction","[{\"question\":\"What cancer-related glycosylation changes are highlighted as common in tumors?\",\"answer\":\"The text emphasizes mucin-type O-glycosylation changes, including incomplete glycan synthesis, increased truncated O-glycans (Tn/T antigens and sialylated forms), and enhanced fucosylation-related expression.\"},{\"question\":\"What is the goal of combining anti-MUC1 with tiliroside in AGS cells?\",\"answer\":\"The study aims to assess the combined effect on cancer-related factors in AGS gastric cancer cells, focusing on MUC1-related signaling and tumor-associated targets.\"},{\"question\":\"How did the combined therapy compare with monotherapy?\",\"answer\":\"The combined action of anti-MUC1 and tiliroside was more effective than monotherapy for multiple targets, including C1GalT1, ST3GalT1, FUT4, Gal-3, NF-κB, Akt mRNAs, and Tn antigen, as well as sialyl T antigen expression.\"}]","Tiliroside Combined with Anti-MUC1 Monoclonal Antibody as Promising Anti-Cancer Strategy in AGS Cancer Cells | PDF",1790228923]